2016—2017年同煤集团总医院铂类药物的不良反应分析
|
摘要
目的汇总同煤集团总医院肿瘤内科铂类抗肿瘤药物的使用情况,对化疗过程中可能出现的不良反应进行分析,促进临床合理、安全用药。方法收集2016年10月—2017年10月同煤集团总医院肿瘤内科所有铂类药物不良反应的报告,并对药物基本使用情况与患者用药信息进行记录和分析。结果共有943例患者使用铂类药物,发生不良反应458例,不良反应发生率为48.57%。铂类药物不良反应在中年女性中发生率较高,肺癌患者最多,占35.59%。不良反应主要表现为血液系统毒性、胃肠道毒性、神经系统毒性。98.03%患者不良反应预后良好。结论临床药师应当密切关注铂类化疗药物的不良反应,预防不良反应的发生,降低不良反应的发生率,保障肿瘤患者用药安全。
Objective To summarize the usage situation of platinum anti-tumor drugs in Department of Medical Oncology in General Hospital of Datong Coal Group, and to analyze the possible adverse reactions in the course of chemotherapy, and to promote the rational and safety medication in clinic. Methods The reports of adverse reactions of induced by platinum drugs in Department of Medical Oncology General Hospital of Datong Coal Group from October 2016 to October 2017 were collected, and the basic usage situation of drugs and the patient's medication information were recorded and analyzed. Results Patients(943 cases) used platinum drugs, while there were 458 cases of adverse reactions, and the rate was 48.57%. Middle-aged women had higher incidence of adverse reactions. And more were patients with lung cancer, and the incidence of adverse reactions was 35.59%. The main performances of adverse reactions were blood system toxicity, gastrointestinal system toxicity, and nerve system toxicity. The prognosis of 98.03% patients was favorable. Conclusion Clinical pharmacists should pay close attention to the adverse reactions of platinum chemotherapy drugs, prevent the occurrence of adverse reactions, reduce the incidence of adverse reactions, and ensure the safety medication in cancer patients.
Objective To summarize the usage situation of platinum anti-tumor drugs in Department of Medical Oncology in General Hospital of Datong Coal Group, and to analyze the possible adverse reactions in the course of chemotherapy, and to promote the rational and safety medication in clinic. Methods The reports of adverse reactions of induced by platinum drugs in Department of Medical Oncology General Hospital of Datong Coal Group from October 2016 to October 2017 were collected, and the basic usage situation of drugs and the patient's medication information were recorded and analyzed. Results Patients(943 cases) used platinum drugs, while there were 458 cases of adverse reactions, and the rate was 48.57%. Middle-aged women had higher incidence of adverse reactions. And more were patients with lung cancer, and the incidence of adverse reactions was 35.59%. The main performances of adverse reactions were blood system toxicity, gastrointestinal system toxicity, and nerve system toxicity. The prognosis of 98.03% patients was favorable. Conclusion Clinical pharmacists should pay close attention to the adverse reactions of platinum chemotherapy drugs, prevent the occurrence of adverse reactions, reduce the incidence of adverse reactions, and ensure the safety medication in cancer patients.
引文
[1]余邦良,马亚平,刘全忠,等.铂类抗癌药物研究进展[J].海南大学学报:自然科学版,2005,23(1):72-80.
[2]杨一昆,普绍平,高文桂.顺铂的应用及铂族金属抗癌药物的研究进展[J].中国新药杂志,1999,8(12):797-800.
[3]刘剑,徐韶东.常见铂类抗肿瘤药物不良反应的比较与防治[J].中国药房,2013,24(30):2857-2859.
[4]CFDA.药品ADR报告和监测管理办法[EB/OL].(2011-05-04)[2017-10-10].http://www.sfda.gov.cn/WS01/CL0053/24477.html.
[5]CFDA.药品ADR报告和监测工作手册[EB/OL].(2013-12-15)[2017-10-10].http://www.cdr.gov.cn/xzzx/hyzl/hyzl2013nd/201304/t20130426_5436.html.
[6]王理伟,蔡讯.铂类药物的不良反应及其防治[J].上海医药,2013,34(23):6-10.
[7]翟美霞,徐金中.抗肿瘤药物的不良反应分析与防治[J].医药导报,2010,29(3):394-396.
[8]赖树清,须媚.抗肿瘤药洛铂:lobaplatin[J].世界临床药物,2005,26(5):315.
[9]Kelly H,Goldberg R M.Systemic therapy for metastatic cobrectalcancer current options,current evidence[J].J Clin Oncol,2005,23(20):4553-4560.
[10]王林,李新平.铂类药物的毒性作用与预防措施[J].医药导报,2005,24(3):254-256.
[2]杨一昆,普绍平,高文桂.顺铂的应用及铂族金属抗癌药物的研究进展[J].中国新药杂志,1999,8(12):797-800.
[3]刘剑,徐韶东.常见铂类抗肿瘤药物不良反应的比较与防治[J].中国药房,2013,24(30):2857-2859.
[4]CFDA.药品ADR报告和监测管理办法[EB/OL].(2011-05-04)[2017-10-10].http://www.sfda.gov.cn/WS01/CL0053/24477.html.
[5]CFDA.药品ADR报告和监测工作手册[EB/OL].(2013-12-15)[2017-10-10].http://www.cdr.gov.cn/xzzx/hyzl/hyzl2013nd/201304/t20130426_5436.html.
[6]王理伟,蔡讯.铂类药物的不良反应及其防治[J].上海医药,2013,34(23):6-10.
[7]翟美霞,徐金中.抗肿瘤药物的不良反应分析与防治[J].医药导报,2010,29(3):394-396.
[8]赖树清,须媚.抗肿瘤药洛铂:lobaplatin[J].世界临床药物,2005,26(5):315.
[9]Kelly H,Goldberg R M.Systemic therapy for metastatic cobrectalcancer current options,current evidence[J].J Clin Oncol,2005,23(20):4553-4560.
[10]王林,李新平.铂类药物的毒性作用与预防措施[J].医药导报,2005,24(3):254-256.